AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.
Overview
Investors often weigh high-margin drug developers against massive healthcare service providers when building a portfolio. Choosing between AbbVie (NYSE:ABBV) and CVS Health (NYSE:CVS) requires balancing biotech growth against retail stability.
AbbVie focuses on discovering and commercializing advanced therapies, while CVS Health operates an integrated model spanning insurance, pharmacies, and primary care clinics. Both companies play critical roles in the healthcare sector but offer very different risk and reward profiles for retail investors seeking long-term exposure in the current market.
Details
AbbVie operates as a global biopharmaceutical giant among healthcare stocks, selling advanced therapies to wholesale distributors and government agencies. Its primary customers include McKesson, Cardinal Health, and Cencora, which represent nearly all U.S. sales. Customer concentration like this adds a layer of risk to the business. The company recently moved to strengthen its pipeline by announcing a $10.9 billion acquisition of Apogee Therapeutics in June 2026.
Source
Originally published at www.fool.com.